AgingResearch.News

Papers by Petter Bjornstad

13 results

  2. Nature Medicine

    Semaglutide may protect kidneys by reducing vascular resistance

    In a 52-week trial of 106 people with type 2 diabetes and chronic kidney disease, semaglutide reduced renal vascular resistance without altering coprimary imaging…In a 52-week trial of 106 people with type 2 diabetes and chronic kidney disease, semaglutide reduced renal vascular resistance without altering coprimary imaging endpoints.

    Randomised trial in 106 peopleSemaglutide
    Paper
  3. Lancet

    Retatrutide reduces bodyweight in obesity and type 2 diabetes

    Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.

    Randomised trial in 1,152 peopleRetatrutide
    Paper